Aptose Biosciences Inc.

Posters & Presentations

All Poster Presentation
January 6, 2021 Presentation

Aptose Biosciences Inc Corporate Presentation January 2021

Aptose Biosciences Inc Corporate Presentation January 2021: View Presentation
December 6, 2020 Presentation

Aptose Corporate Update at ASH 2020

Aptose Corporate Update at ASH 2020: View Presentation
December 6, 2020 Poster

2020 ASH Poster - A Phase 1 a/b Dose Escalation Study of the Mutation Agnostic BTK/FLT3 Inhibitor CG-806 in Patients with R/R CLL/SLL or NHL

2020 ASH Poster - A Phase 1 a/b Dose Escalation Study of the Mutation Agnostic BTK/FLT3 Inhibitor CG-806 in Patients with R/R CLL/SLL or NHL : View Poster
December 5, 2020 Poster

2020 ASH Poster - A Phase 1a/b Dose Escalation Study of the MYC Repressor APTO-253 in Patients with R/R AML or HR-MDS

2020 ASH Poster - A Phase 1a/b Dose Escalation Study of the MYC Repressor APTO-253 in Patients with R/R AML or HR-MDS: View Poster
June 22, 2020 Poster

2020 AACR Poster - CG-806, a First-in-Class FLT3/BTK Inhibitor, and Venetoclax Synergize to Inhibit Cell Proliferation and to Induce Apoptosis in Aggressive B-cell Lymphomas

2020 AACR Poster - CG-806, a First-in-Class FLT3/BTK Inhibitor, and Venetoclax Synergize to Inhibit Cell Proliferation and to Induce Apoptosis in Aggressive B-cell Lymphomas: View Poster
June 12, 2020 Poster

2020 EHA Poster - Early Clinical Findings from a Phase 1 a/b Dose Escalation Trial to Evaluate the Safety and Tolerability of CG-806 in Patients with R/R CLL/SLL or NHL

2020 EHA Poster - Early Clinical Findings from a Phase 1 a/b Dose Escalation Trial to Evaluate the Safety and Tolerability of CG-806 in Patients with R/R CLL/SLL or NHL: View Poster
April 27, 2020 Presentation

2020 AACR Presentation - Early clinical findings from a Phase 1a/b dose escalation trial to evaluate the safety and tolerability of CG-806 in patients with R/R CLL/SLL or NHL

2020 AACR Presentation - Early clinical findings from a Phase 1a/b dose escalation trial to evaluate the safety and tolerability of CG-806 in patients with R/R CLL/SLL or NHL: View Presentation
February 5, 2020 Presentation

Key Opinion Leader Symposium: CG-806 for AML

Key Opinion Leader Symposium: CG-806 for AML: View Presentation
December 9, 2019 Poster

2019 ASH Poster - Synergistic Targeting of BTK and E-Selectin/CXCR4 in the Microenvironment of Mantle Cell Lymphomas

2019 ASH Poster - Synergistic Targeting of BTK and E-Selectin/CXCR4 in the Microenvironment of Mantle Cell Lymphomas: View Poster